by Tamiflu (Oseltamivir Phosphate) is an antiviral medication used to treat the flu caused by influenza virus types A and B. Tamiflu helps reduce the severity and duration of influenza symptoms when started within 48 hours of the onset of symptoms.
The Global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights
Market key trends:
One of the key trends in the Tamiflu (Oseltamivir Phosphate) market is the increasing prevalence of influenza cases globally. As per the data published by Center for Disease Control and Prevention, during 2019-2020 season, there were an estimated 410,000-740,000 hospitalizations due to influenza. The increase in flu cases has augmented the demand for antiviral drugs like Tamiflu for its treatment. Moreover, rising awareness about the influenza and its effects have also fueled the growth of Tamiflu (Oseltamivir Phosphate) market over the forecast period.
SWOT Analysis
Strength: Tamiflu is one of the first line treatment options for influenza. It is available as an oral capsule which offers ease of administration compared to other available influenza treatments.
Weakness: Tamiflu needs to be administered within 48 hours of onset of symptoms to be effective. Its effectiveness reduces if delayed. It is also associated with some mild side effects like nausea and vomiting.
Opportunity: Increasing incidence of influenza outbreaks globally presents an opportunity to increase Tamiflu usage. Growing awareness about the importance of early treatment for influenza also supports the market growth.
Threats: Patent expiration of Tamiflu threatens its market share as cheaper generic versions become available. Development of new anti-influenza drugs can replace Tamiflu as first line treatment over time.
Key Takeaways:
The Global Tamiflu (Oseltamivir Phosphate) Market Size is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insightsis expected to witness high growth, exhibiting CAGR of 3.1% over the forecast period, due to increasing incidence of influenza outbreaks worldwide.
Regional analysis:
North America dominated the Tamiflu market in 2023 with a share of over 35%, due to high diagnosis and treatment rates for influenza in the US. Asia Pacific is expected to grow at the fastest rate during the forecast period supported by increasing healthcare expenditure and expanding healthcare infrastructure in countries like China and India.
Key players operating in the Tamiflu (Oseltamivir Phosphate) market are Roche, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Mylan N.V., Apotex Inc., Sandoz AG, Accord Healthcare Ltd. Roche led the market in 2023 while loss of patent exclusivity has led to the entry of generic drug manufacturers contributing to market growth.
